Literature DB >> 20147979

Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation.

T Lion1, K Kosulin, C Landlinger, M Rauch, S Preuner, D Jugovic, U Pötschger, A Lawitschka, C Peters, G Fritsch, S Matthes-Martin.   

Abstract

Invasive adenovirus (AdV) infections are associated with high morbidity and mortality in allogeneic stem cell transplant recipients. We observed that molecular detection of the virus in stool specimens commonly precedes AdV viremia, suggesting that intestinal infections may represent a common source of virus dissemination. To address this notion, we have investigated 153 consecutive allogeneic transplantations in 138 pediatric patients by quantitative monitoring of AdV in stool specimens and peripheral blood by a pan-adenovirus real-time (RQ)-PCR approach. AdV was detectable in serial stool specimens in all cases of AdV viremia during the post-transplant course (P<0.0001). The incidence of AdV viremia in individuals with peak virus levels in stool specimens above 1 x 10E6 copies per gram (n=22) was 73% vs 0% in patients with AdV levels in stool specimens below this threshold (n=29; P<0.0001). Serial measurement of AdV levels in stool specimens by RQ-PCR permitted early diagnosis of impending invasive infection with a sensitivity and specificity of 100% (95% confidence interval (CI) 96-100%) and 83% (95% CI 67-92%), respectively. The median time span between detection of AdV loads in stool specimens above 1 x 10E6 copies per gram and first observation of viremia was 11 days (range 0-192). Quantitative monitoring of the AdV load in stool specimens therefore provides a rationale for early initiation of antiviral treatment with the aim of preventing progression to life-threatening invasive infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147979     DOI: 10.1038/leu.2010.4

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  54 in total

1.  Adenoviral infection presenting as an isolated central nervous system disease without detectable viremia in two children after stem cell transplantation.

Authors:  Pierre Frange; Régis Peffault de Latour; Cécile Arnaud; Nathalie Boddaert; Mehdi Oualha; Véronique Avettand-Fenoel; Françoise Bernaudin; Claire Aguilar; Christine Barnerias; Marianne Leruez-Ville; Fabien Touzot; Olivier Lortholary; Alain Fischer; Stéphane Blanche
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

Review 2.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Persistent recipient-derived human adenovirus (HAdV)-specific T cells promote HAdV control after allogeneic hematopoietic stem cell transplantation.

Authors:  R E Schultze-Florey; S Tischer; W Kühnau; A Heim; B Eiz-Vesper; B Maecker-Kolhoff
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

4.  Adenovirus: current epidemiology and emerging approaches to prevention and treatment.

Authors:  Uriel Sandkovsky; Luciano Vargas; Diana F Florescu
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

5.  USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses.

Authors:  Karoly Toth; Jacqueline F Spencer; Baoling Ying; Ann E Tollefson; Caroll B Hartline; Eric T Richard; Jiajun Fan; Jinglei Lyu; Boris A Kashemirov; Cheryl Harteg; Dawn Reyna; Elke Lipka; Mark N Prichard; Charles E McKenna; William S M Wold
Journal:  Antiviral Res       Date:  2018-03-03       Impact factor: 5.970

6.  Impact of adenoviral stool load on adenoviremia in pediatric hematopoietic stem cell transplant recipients.

Authors:  Ashok Srinivasan; Corie Klepper; Anusha Sunkara; Guolian Kang; Jeanne Carr; Zhengming Gu; Wing Leung; Randall T Hayden
Journal:  Pediatr Infect Dis J       Date:  2015-06       Impact factor: 2.129

Review 7.  How I treat adenovirus in hematopoietic stem cell transplant recipients.

Authors:  Caroline A Lindemans; Ann M Leen; Jaap Jan Boelens
Journal:  Blood       Date:  2010-09-13       Impact factor: 22.113

8.  Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.

Authors:  R Geyeregger; C Freimüller; J Stemberger; G Fischer; V Witt; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

9.  Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Authors:  Yeon Joo Lee; Dick Chung; Kun Xiao; Esperanza B Papadopoulos; Juliet N Barker; Trudy N Small; Sergio A Giralt; Junting Zheng; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

10.  New drug on the horizon for treating adenovirus.

Authors:  William S M Wold; Karoly Toth
Journal:  Expert Opin Pharmacother       Date:  2015-09-02       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.